- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07278479
Studie van [212Pb]Pb-DOTAM-MAM279 bij patiënten met kleincellig longcarcinoom en andere vaste tumoren die DLL3 tot expressie brengen
Een Fase 1/2a-studie om de veiligheid, verdraagbaarheid en werkzaamheid van [212Pb]Pb-DOTAM-MAM279 te beoordelen bij patiënten met kleincellig longcarcinoom en andere vaste tumoren die DLL3 tot expressie brengen
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [212Pb]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumors.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This is a phase I/IIa, open-label, multi-center study to evaluate the safety, tolerability, dosimetry, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of [212Pb]Pb-MP0712 in patients with SCLC and other advanced DLL3-expressing solid tumors. The study consists of a dose escalation part, followed by a dose expansion part. Once the recommended radioactive dose(s) [212Pb]Pb-MP0712 for further clinical evaluation are determined, the dose expansion part will further characterize the safety, tolerability, and preliminary anti-tumor activity of [212Pb]Pb-MP0712. The study will enable evaluation of the safety, dosimetry, PK, and imaging properties of [203Pb]Pb-MP0712.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Medical Director MPAG
- Telefoonnummer: +41 44 755 77 00
- E-mail: info@molecularpartners.com
Studie Locaties
-
-
Florida
-
Tampa, Florida, Verenigde Staten, 33612
- Werving
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30322
- Werving
- Emory University Hospital
-
Contact:
- Ryan Hanula
- Telefoonnummer: 404-778-5141
- E-mail: rhanula@emory.edu
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60637
- Werving
- University of Chicago
-
-
Maryland
-
Glen Burnie, Maryland, Verenigde Staten, 21061
- Werving
- United Theranostics
-
Contact:
- Amanda Huggins
- Telefoonnummer: 667-HOPENOW
- E-mail: clinicaltrial@unithera.com
-
-
Nebraska
-
Omaha, Nebraska, Verenigde Staten, 68130
- Werving
- Nebraska Cancer Specialists
-
Contact:
- Research Director
- Telefoonnummer: 402-955-2691
- E-mail: clinicaltrials@nebraskacancer.com
-
-
New Jersey
-
Princeton, New Jersey, Verenigde Staten, 08540
- Werving
- United Theranostics
-
Contact:
- Amanda Huggins
- Telefoonnummer: 667-HOPENOW
- E-mail: clinicaltrial@unithera.com
-
-
Ohio
-
Cleveland, Ohio, Verenigde Staten, 44106
- Werving
- University Hospitals Cleveland Medical Center
-
Contact:
- Dr A.Dowlati
- Telefoonnummer: 216-368-1122
- E-mail: afshin.dowlati@uhhospitals.org
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- The University of Texas MD Anderson Cancer Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Key Inclusion Criteria:
-
Age ≥ 18 years old
-
Histologically or cytologically confirmed: I. advanced extensive or limited SCLC or LC NECs of the lung
- SCLC (extensive stage, or limited stage) patients with progression or recurrence following at least two prior line of systemic platinum based therapy and immunotherapy or are not suitable or tolerating the standard of care treatment as second line of systemic therapy, or
- LC NEC of the lung patients with progression or recurrence following at least one prior line of systemic therapy, or II. epNECs with progression or recurrence following at least one prior line of systemic therapy:
- Gastroenteropancreatic NECs (GEPNEC), or
- Cervical NECs, or
- Bladder NECs, or
- other epNECs with previously confirmed DLL3 expression by IHC.
- Patients with prior DLL3-targeted therapy are allowed.
-
For epNECs in Part 1 and Part 2 and SCLC or LC NECs of the lung in Part 2: DLL3-positivity by [203Pb]Pb-DOTAM-MAM279 SPECT/CT
-
Radiographically documented disease progression or recurrence during or after the last line of systemic treatment therapy
-
At least one measurable disease per RECIST v1.1.
-
Adequate bone marrow reserve and organ function as demonstrated by complete blood count, and biochemistry in blood and urine at Screening
-
Adequate blood counts: Hemoglobin ≥9 g/dL; Absolute neutrophil count (ANC) ≥1.5 × 10^9/L; Platelets ≥100 × 10^9/L; White blood cells (WBC) ≥2.5 x 10^9/L;
-
Adequate hepatic function
-
Adequate renal function: Calculated glomerular filtration rate (GFR) >60mL/min (using Cockroft-Gault formula).
-
Patients with known central nervous system (CNS) metastasis will be eligible if they are clinically stable.
Key Exclusion Criteria:
- Uncontrolled intercurrent illness
- Patients who have not had resolution of all clinically significant toxic effects of prior systemic cancer therapy, surgery, or radiotherapy to Grade ≤1 (except for grade ≤2 alopecia, or stable grade 2 sensory neuropathy, according to the last CTCAE version).
- Active clinically significant cardiac disease
- Evidence of interstitial lung disease or active, non-infectious pneumonitis.
- History of other malignancy within the past 2 years with exceptions.
Other protocol-defined inclusion/exclusion criteria may apply.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Sequentiële toewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: [203Pb]Pb-DOTAM-MAM279/[212Pb]Pb-DOTAM-MAM279
Patients will receive [203Pb]Pb-DOTAM-MAM279 for Imaging/Dosimetry followed by [212Pb]Pb-DOTAM-MAM279 for treatment |
Radioligand Therapy
Andere namen:
Radioligand Imaging Agent
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
To assess incidence and severity of safety events following administration of [212Pb]Pb-DOTAM-MAM279
Tijdsspanne: until 5 years after last dose
|
Type, frequency and severity of adverse events (AEs), and serious adverse events (SAEs), Adverse events of special interest (AESI) and Dose Limiting Toxicities (DLT) using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) |
until 5 years after last dose
|
|
To assess dose modifications of [212Pb]Pb-DOTAM-MAM279
Tijdsspanne: until 5 years after last dose
|
Frequency and duration of dose changes |
until 5 years after last dose
|
|
To estimate the maximum tolerated dose (MTD) and/or to define the recommended phase 2 dose (RP2D) for SCLC/LCNEC of the lung and epNECs
Tijdsspanne: Phase 1, from start of treatment to end of first cycle (day 1 - 28)
|
Incidence of dose limiting toxicities |
Phase 1, from start of treatment to end of first cycle (day 1 - 28)
|
|
To evaluate the preliminary anti-tumor activity of [212Pb]Pb-DOTAM-MAM279 in the dose expansion part
Tijdsspanne: Phase 2a only; 12 months
|
Objective Response Rate (ORR) in the expansion phase ORR is defined as the percentage of patients with partial response (PR) or complete response (CR) as per RECIST v1.1 |
Phase 2a only; 12 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
To assess maximum concentration (Cmax) of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279
Tijdsspanne: up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
|
Blood and serum samples will be drawn to determine maximum concentration (Cmax) of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279 |
up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
|
|
To assess the area under the curve (AUC) from time 0 to the time of the last quantifiable concentration of [203Pb]Pb-DOTAM-MAM279
Tijdsspanne: up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
|
Blood and serum samples will be drawn to determine AUC of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279 |
up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
|
|
To assess half-live(s) (t½) of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279
Tijdsspanne: up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
|
Blood and serum samples will be drawn to determine half-live(s) (t½) of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279 |
up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
|
|
To assess the clearance (CL) of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279
Tijdsspanne: up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
|
Blood and serum samples will be drawn to determine clearance (CL) of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279 |
up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
|
|
To assess the volume of distribution (Vd) of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279
Tijdsspanne: up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
|
Blood and serum samples will be drawn to determine the volume of distribution (Vd) of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279 |
up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
|
|
To quantitatively predict radiation absorbed doses for therapeutic [212Pb]Pb-DOTAM-MAM279 from [203Pb]Pb-DOTAM-MAM279
Tijdsspanne: Phase 1; up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration
|
Estimation of [212Pb]Pb-DOTAM-MAM279 absorbed dose for healthy organs and tumor lesions based on dosimetry analysis of [203Pb]Pb-DOTAM-MAM279 |
Phase 1; up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration
|
|
To assess incidence and severity of safety events following administration of [203Pb]Pb-DOTAM-MAM279
Tijdsspanne: up to 10 days following [203Pb]Pb-DOTAM-MAM279 administration
|
Type, frequency and severity of adverse events (AEs) and serious adverse events (SAEs) using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 |
up to 10 days following [203Pb]Pb-DOTAM-MAM279 administration
|
|
To evaluate PFS
Tijdsspanne: Phase 2a only; 12 months
|
Progression-Free Survival (PFS) determined as the time from C1D1 to the date of progression, defined as the first documented progression as per RECIST v1.1 or death for any cause |
Phase 2a only; 12 months
|
|
To evaluate DoR
Tijdsspanne: Phase 2a only; 12 months
|
Duration of response (DoR) in patients with a CR or PR from date of first date of response to the date of RECIST 1.1 progression or death |
Phase 2a only; 12 months
|
|
To evaluate DCR
Tijdsspanne: Phase 2a only; 12 months
|
Disease control rate (DCR) defined as the percentage of patients who have achieved CR, PR, or stable disease (SD) |
Phase 2a only; 12 months
|
|
To evaluate OS
Tijdsspanne: Phase 2a only; approx. 5 years
|
Overall survival (OS) defined as the time from C1D1 to death from any cause |
Phase 2a only; approx. 5 years
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per site
- Neoplasmata
- Ziekten van de luchtwegen
- Neoplasmata per histologisch type
- Longziekten
- Neoplasmata, glandulair en epitheel
- Adenocarcinoom
- Neoplasmata van de luchtwegen
- Thoracale neoplasmata
- Longneoplasmata
- Carcinoom
- Neuro-ectodermale tumoren
- Neoplasmata, kiemcellen en embryonaal
- Neoplasmata, zenuwweefsel
- Carcinoom, bronchogeen
- Bronchiale neoplasmata
- Neuro-endocriene tumoren
- Kleincellig longcarcinoom
- Carcinoom, neuro-endocrien
Andere studie-ID-nummers
- MP0712-CP101
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .